Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002347645 | SCV002649620 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-09-20 | criteria provided, single submitter | clinical testing | The c.5711_5713delTTC variant (also known as p.L1904del) is located in coding exon 10 of the BRCA2 gene. This variant results from an in-frame TTC deletion at nucleotide positions 5711 to 5713. This results in the in-frame deletion of a leucine at codon 1904. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003096849 | SCV003202317 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2022-05-24 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). This variant, c.5711_5713del, results in the deletion of 1 amino acid(s) of the BRCA2 protein (p.Leu1904del), but otherwise preserves the integrity of the reading frame. This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. |